Belimumab for refractory manifestations of cutaneous lupus: A multicenter, retrospective observational study of 16 patients

To the Editor: Belimumab is a fully humanized monoclonal antibody against B-lymphocyte stimulator approved for systemic lupus erythematosus (SLE). A post hoc analysis of the 2 pivotal phase 3 studies showed that belimumab led to a better improvement than placebo on mucocutaneous domains. However, these studies used global scores that do not accurately assess improvement of cutaneous lupus erythematosus (CLE).1 There are very few data on the efficacy of belimumab using appropriate tools to assess CLE activity, particularly for chronic subtypes.